Idalbiclo Tablets 40/12.5 mg

Adult dose

The recommended initial dose of this drug is 40/12.5 mg, taken with water regardless of meals. The antihypertensive effect usually becomes apparent within 1-2 weeks, and if blood pressure control is needed after 2-4 weeks, the dose can be increased to 40/25 mg. Doses exceeding 40/25 mg are not useful. The recommended initial dose is 40/12.5 mg once daily.

This medication should be discontinued in pregnant women, as it can cause serious harm to the fetus and newborn during the second and third trimesters. Patients with impaired liver function or ongoing liver disease should exercise caution, as this medication can cause serious issues such as hepatic coma. Severely renal impaired patients may experience elevated blood nitrogen levels due to the diuretic component of this drug, risking side effects from drug accumulation. Those with allergies to this drug or its components, pregnant or potentially pregnant women, and nursing mothers should not take this medication. Patients with anuria, severe hepatic impairment, or renal impairment, as well as those with hyponatremia or hypercalcemia, should also avoid this drug. Patients with a history of gout or hyperuricemia, those undergoing lithium treatment, or those taking medications that pose a risk of specific cardiac arrhythmias need to be cautious when taking this medication. In states of low blood volume or sodium depletion, hypotension symptoms may occur during early treatment; therefore, correction of the condition before use and immediate lying down in case of hypotension is necessary. Patients with impaired kidney function should have their renal function regularly monitored during treatment and discontinue use if deterioration occurs. Due to a lack of established safety in severely impaired hepatic patients, caution is advised when administering this drug. This medication may cause electrolyte imbalances such as hypokalemia, hyponatremia, and hypercalcemia, so frequent blood tests to check electrolyte levels are necessary. Hypokalemia, in particular, can be risky for patients with heart disease, so caution is required. Patients with hyperuricemia or gout may experience worsened symptoms when taking this drug; avoiding it is recommended. When used with other antihypertensive agents, the risk of hypotension, hyperkalemia, and renal function decline may increase, so combinations should be avoided or used with caution. Consult healthcare professionals immediately if blood pressure drops too low or there are renal function issues. Dizziness or drowsiness may occur during use; caution is needed when driving or operating heavy machinery. Adverse reactions may include increased serum creatinine, dizziness, hypotension, diarrhea, nausea, rash, etc.; if symptoms are severe or persistent, notify healthcare professionals. Pregnant or planning to become pregnant women should refrain from taking this medication, and it is not recommended for nursing mothers. In case of overdose, symptoms like hypotension, dizziness, and electrolyte imbalance may occur, so immediate medical attention is required. This medication should be stored out of reach of children and kept in its original packaging, away from light and moisture.

Serious side effects

Urticaria, severe swelling (edema), serious angioedema, respiratory distress, neurological disorders (syncope, pre-syncope, tremor), liver disorders (cholestasis or jaundice), subdural hematoma, acute kidney injury, acute renal failure, subdural hematoma

Mild side effects

• Increased serum creatinine
• headache
• dizziness
• increased serum uric acid
• hyperuricemia
• hypokalemia
• increased serum potassium
• hyponatremia
• decreased serum sodium
• gout

This medication should be stored in a tightly sealed container protected from light, ideally at a temperature between 1 to 30 degrees Celsius in a room. It should also be kept in a dry place to maintain its effectiveness.

Appearance

Light red, round, biconvex film-coated tablet

Package unit

28 tablets (14 tablets/PTP X 2), 56 tablets (14 tablets/PTP X 4)